Levetiracetam
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Premenstrual Dysphoric Disorder
Conditions
Premenstrual Dysphoric Disorder
Trial Timeline
Nov 1, 2003 โ Oct 1, 2006
NCT ID
NCT00518570About Levetiracetam
Levetiracetam is a pre-clinical stage product being developed by UCB for Premenstrual Dysphoric Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00518570. Target conditions include Premenstrual Dysphoric Disorder.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03340064 | Phase 3 | Completed |
| NCT01618877 | Phase 1 | Completed |
| NCT01407523 | Phase 2 | Completed |
| NCT01398956 | Phase 3 | Completed |
| NCT01292837 | Phase 3 | Completed |
| NCT01063764 | Phase 3 | Completed |
| NCT00505934 | Phase 2 | Completed |
| NCT00627133 | Phase 2 | Withdrawn |
| NCT00535392 | Phase 2 | Completed |
| NCT00376766 | Phase 3 | Terminated |
| NCT00361010 | Pre-clinical | Completed |
| NCT01318408 | Approved | Completed |
| NCT00367432 | Phase 3 | Completed |
| NCT00291655 | Phase 3 | Completed |
| NCT00324454 | Phase 2 | Completed |
| NCT00319605 | Pre-clinical | Completed |
| NCT00307450 | Approved | Completed |
| NCT00279617 | Phase 3 | Completed |
| NCT00325182 | Approved | Completed |
| NCT00252954 | Approved | Completed |
Competing Products
5 competing products in Premenstrual Dysphoric Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| paroxetine | Novo Nordisk | Approved | 84 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Drospirenone and ethinyl estradiol + Placebo | Bayer | Pre-clinical | 20 |
| EE20/DRSP(YAZ, BAY86-5300) + Placebo | Bayer | Phase 3 | 74 |